Related Experiment Video
Updated: Jul 16, 2026
08:29
Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling
Published on: August 1, 2016
Tuning cardiac performance in ischemic heart disease and failure by modulating myofilament function
Sharlene M Day1, Margaret V Westfall, Joseph M Metzger
1Department of Internal Medicine, University of Michigan, 1150 W. Medical Center Drive, 7301 MSRB III, Ann Arbor, MI 48109-0644, USA. sday@umich.edu
Journal of Molecular Medicine (Berlin, Germany)
|March 31, 2007
Summary
Cardiac myofilaments, crucial for heart function, show altered calcium sensitivity in diseases like ischemia and heart failure. A modified troponin I protein offers potential therapeutic benefits across various cardiac conditions.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Cardiac Pathophysiology
Background:
- Cardiac myofilaments, organized protein arrays, regulate heart contraction and relaxation.
- Altered myofilament protein interactions are linked to cardiac dysfunction in disease states.
- Myofilament calcium (Ca2+) sensitivity is reduced during acute myocardial ischemia due to acidosis.
Purpose of the Study:
- To elucidate the role of myofilaments in cardiac pathophysiology, focusing on troponin I.
- To discuss the therapeutic potential of a genetically engineered cardiac troponin I variant.
Main Methods:
- Review of existing literature on myofilament function in cardiac diseases.
- Analysis of the molecular mechanisms affecting myofilament Ca2+ sensitivity.
- Discussion of a genetically engineered troponin I with a histidine substitution.
Main Results:
- Myofilament Ca2+ sensitivity is compromised in stunned myocardium post-ischemia.
- Decreased troponin I phosphorylation can increase myofilament Ca2+ sensitivity in chronic heart failure.
- A genetically engineered cardiac troponin I variant shows promise for various cardiac conditions.
Conclusions:
- Myofilaments, particularly troponin I, play a central role in the pathophysiology of ischemia and heart failure.
- The engineered troponin I variant demonstrates potential benefits in models of hypoxia, ischemia, ischemia-reperfusion, and chronic heart failure.
Related Concept Videos
01:29Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...